[go: up one dir, main page]

CN103233028A - Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence - Google Patents

Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence Download PDF

Info

Publication number
CN103233028A
CN103233028A CN2013100286682A CN201310028668A CN103233028A CN 103233028 A CN103233028 A CN 103233028A CN 2013100286682 A CN2013100286682 A CN 2013100286682A CN 201310028668 A CN201310028668 A CN 201310028668A CN 103233028 A CN103233028 A CN 103233028A
Authority
CN
China
Prior art keywords
cas9
dna
nls
sequence
flag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013100286682A
Other languages
Chinese (zh)
Other versions
CN103233028B (en
Inventor
沈彬
黄行许
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANJING SYNC BIOTECH CO Ltd
Original Assignee
NANJING SYNC BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING SYNC BIOTECH CO Ltd filed Critical NANJING SYNC BIOTECH CO Ltd
Priority to CN201310028668.2A priority Critical patent/CN103233028B/en
Publication of CN103233028A publication Critical patent/CN103233028A/en
Application granted granted Critical
Publication of CN103233028B publication Critical patent/CN103233028B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构DNA序列,属于基因工程领域。该方法的步骤为:(1)CRISPR/Cas9和嵌合RNA的设计与构建;(2)Cas9mRNA体内翻译后形成Cas9核酸酶与嵌合RNA结合,实现定点剪切,剪切后产生DNA双链断裂,通过诱导细胞自身天然的DNA修复过程“非同源末端连接”来引入外源DNA,从而修改细胞内源基因。该方法步骤简单,识别位点灵活且消耗低。The invention discloses a eukaryotic gene targeting method and a helical structure DNA sequence without species limitation and without biological safety problems, belonging to the field of genetic engineering. The steps of the method are: (1) Design and construction of CRISPR/Cas9 and chimeric RNA; (2) Cas9 mRNA is translated in vivo to form a Cas9 nuclease that binds to the chimeric RNA to achieve fixed-point shearing and generate DNA double strands after shearing Fragmentation, by inducing the cell's own natural DNA repair process "non-homologous end joining" to introduce foreign DNA, thereby modifying the cell's endogenous genes. The method has simple steps, flexible recognition sites and low consumption.

Description

A kind of eukaryotic gene target practice method and spirane structure dna sequence dna that does not have species restriction lifeless matter safety issue
Technical field
The invention belongs to the genetically engineered field, more particularly, relate to a kind of eukaryotic gene target practice method and spirane structure dna sequence dna that does not have species restriction lifeless matter safety issue.
Background technology
Gene targeting (gene targeting) technology is a kind of experimental technique of directed change organism genetic information.Along with development of biology, Zinc finger nuclease (ZFN) technology and activating transcription factor sample effector nuclease (TALEN) technology are applied in the gene targeting in recent years, and these two technology have improved the specificity of directed modification greatly.ZFN is made of a DNA differential threshold and a non-specific endonuclease.The DNA differential threshold is to be composed in series (general 3~4) by a series of Cys2-His2 zinc finger proteins (zinc-fingers), each zinc finger protein identification and in conjunction with a special triplet base.A plurality of zinc finger proteins can be together in series and form one section special base sequence of a zinc finger protein group identification, and the non-specific endonuclease that links to each other with the zinc finger protein group is to shear the territory from the DNA that 96 amino-acid residues of the C end of FokI are formed.FokI is a kind of restriction enzyme from Flavobacterium okeanokoites, only when the dimer state, just there is enzyme to cut activity, each FokI monomer links to each other with a zinc finger protein group and constitutes a ZFN, identify specific site, when two recognition sites at a distance of appropriate apart from the time (6~8bp), two monomer ZFN interact and produce enzymes and cut function.Thereby reach the purpose that the DNA fixed point is sheared.Shear the back and produce the dna double splitting of chain, introduce foreign DNA by the natural DNA repair process of inducing cell self " with the source orientation reparation " or " non-homogeneous terminal connection ", thereby revise the cell native gene.
Zinc finger nuclease technological breakthrough the restrictive factor-target practice efficiency of gene targeting, the efficient of gene targeting is increased to 10-1~10-2 by original 10-6~10-7.But Zinc finger nuclease can produce the phenomenon (off-target) of missing the target in carrying out the genetic modification process, cause cell dosage dependency toxicity.Gupta etc. carry out targeting modification research by different Zinc finger nucleases to zebra fish kdrl locus, utilize the Illumina order-checking to assess the potential site of missing the target, 141 places in the zebra fish, find to have only the site of missing the target of minority to cause the cell accumulated damage.Still need for this reason Zinc finger nuclease-gene targeting is furtherd investigate.
The TALEN technology is the albumen that utilizes phytopathogen Xanthomonas campestris (Xanthomonas) to secrete naturally---be incitant sample effector (TAL effectors, TALEs) function that can identification specificity DNA base pair, design a string suitable TALEs and identify and be attached to any particular sequence, behind TALEs, add a non-specific endonuclease FokI again, construct TALEN, thereby realized cutting off the dna double chain at specific site, by the natural DNA repair process of inducing cell self, in cellular genome, introduce new genetic material.Relative Zinc finger nuclease technology, TALEN can the longer gene order of target, and easier structure.
But up to the present, no matter be ZFN or TALEN, its recognition sequence there are a lot of requirements, can't realize each possible dna sequence dna of target, and the same period that is not easy to carry out two or more sites practice shooting, and assembling ZFN or TALEN albumen also are consuming time, a consumption power and the very high process of cost, and people do not have method cheaply a kind of and that openly can obtain to produce a large amount of ZFNs or TALENs rapidly always.
Summary of the invention
1. invent the technical problem that will solve
At realizing that the limitation that the transformation of specific gene group exists is big, take time and effort and problem that cost is high by ZFNs or TALENs in the prior art, the invention provides a kind of eukaryotic gene target practice method and spirane structure dna sequence dna that does not have species restriction lifeless matter safety issue, this method steps is simple, recognition site flexible and consume low.
2. technical scheme
Inventive principle: utilize procaryotic rule cluster to lack the palindrome at interval and repeat the orientation identification of (CRISPR/Cas) system and shear function, method of the present invention is appraised and decided the position by increasing this system in eukaryote, realization is to the shearing of the specific site of target DNA in the eukaryote, can introduce the sudden change of target dna sequence dna in the repair process after shearing, thereby realize the purpose of gene targeting.
The present invention is achieved through the following technical solutions above-mentioned purpose:
A kind of eukaryotic gene target practice method of not having species restriction lifeless matter safety issue the steps include:
(1) design of CRISPR/Cas9 and chimeric RNA and structure
1) codon of optimization coding Cas9
2) Cas9 nuclease vector construction and Cas9 nuclease mRNA are synthetic
Sequence after optimizing according to step 1), the dna sequence dna of customization composite coding Cas9 nuclease, and it is inserted into respectively in the following expression vector forms: pST1374-Cas9, pST1374-NLS-Flag-Cas9;
Utilize Cas9C-NLS Cla For and two primers of Cas9C-NLS Apa Rev, by dna fragmentation of chain polymerization enzyme reaction (PCR) amplification, use dna fragmentation and the pST1374-NLS-Flag-Cas9 of two digestion with restriction enzyme amplifications of ClaI and ApaI, the dna fragmentation of amplification is inserted into pST1374-NLS-Flag-Cas9, makes up the pST1374-NLS-Flag-Cas9-NLS carrier;
The sequence of three nucleus signal for locating NLS of encoding utilizes Cas9-N-3NLS For and Cas9-N-3NLS Rev primer to come out for the template pcr amplification with the oligonucleotide, the PCR product is behind NheI and two digestion with restriction enzyme of NotI, be inserted in the pST1374-NLS-Flag-Cas9 carrier by same restriction enzyme site again, make up pST1374-3XNLS-Flag-Cas9;
Spirane structure (Helix) dna sequence dna is inserted into after synthetic in the middle of the sequence and coding Cas9 nuclease sequence of code tag albumen Flag through customizing, and forms the pST1374-NLS-Flag-Helix-Cas9 carrier;
The Cas9 system derives from prokaryotic cell prokaryocyte, is difficult to shift to nucleus in eukaryotic cell, thereby can't guarantees that this system realizes its shearing function in eukaryotic cell.The present invention has solved this problem by adding the expression of spirane structure dna sequence dna increase Cas9 in eukaryotic cells nuclear between cell nucleus signal for locating sequence and Cas9 encoding sequence, sees Fig. 2.In this process, used human 293T.
Cas9 nuclease serial carrier obtains Cas9 nuclease mRNA after utilizing T7Ultra Kit in-vitro transcription after the AgeI linearizing, be directly used in gene targeting; Because the unstable of mRNA, can the long-term existence organism in, can not produce further influence to environment, thereby not have the biological safety problem.
3) chimeric RNA's is synthetic
T7 promoter sequence on the chimeric RNA template, be to be that template produces by PCR with synthetic oligonucleotide, utilize T7Shortscript Kit in-vitro transcription to go out chimeric RNA, it comprises crRNA and tracrRNA structure, can be directed in conjunction with the site on the target DNA;
(2) translation back formation Cas9 nuclease is combined with chimeric RNA in the Cas9mRNA body, realize the fixed point shearing, shear the back and produce the dna double splitting of chain, introduce foreign DNA by the natural DNA repair process of inducing cell self " non-homogeneous terminal the connection ", thereby revise the cell native gene.
A kind of spirane structure dna sequence dna, the ability that the consideration convey of this spirane structure dna sequence dna enhancing albumen under nuclear localization signal instructs moves ability and is combined with nucleic acid, its gene order is:
ctggaacccggcgagaagccatacaaatgcccagagtgtggtaaatctttctctcagtctggtgctctgaccagacaccagcggacccacactaga。
3. beneficial effect
Than prior art, the invention has the advantages that:
(1) accuracy is higher.Adopt method of the present invention, as long as there is the difference of any base pair between RNA target sequence and the genome sequence, Cas9 not can in conjunction with, thereby can't realize shearing to DNA;
(2) genome multidigit point is practiced shooting.Adopt method of the present invention, can carry out a plurality of sites on the target gene simultaneously and shear, realize the purpose of genome manipulation;
(3) use is more convenient, and expense is lower.Be the recognition sequence that ZFN or TALEN need change the nucleases front at different target spots, the synthetic or assembling of these recognition sequences take time and effort and expense very high.In the method for the present invention, the CRISPR/Cas system only need change the specific recognition that very short RNA sequence just can realize different loci.In the foundation of animal genetic engineering model, if use ZFN or TALEN technology, also ZFN or TALEN plasmid to be transcribed into mRNA, this has increased the difficulty of expense and experiment again, adopt the CRISPR/Cas system only need transcribe a Cas nuclease and just can finish repeatedly experiment, greatly reduced cost;
(4) lifeless matter safety issue.The present invention takes mRNA and RNA as the gene targeting starting material, uses resistant gene without any screening, thereby does not have the biological safety problem;
(5) adopt method of the present invention, no species restriction.
Description of drawings
Fig. 1 is combined with chimeric RNA for Cas9 and is realized that the fixed point shearing causes dna double chain-breaking process synoptic diagram;
Fig. 2 is that the Laser Scanning Confocal Microscope of each carrier of Cas9 nuclease is taken fluorescence photo.
Embodiment
Below in conjunction with accompanying drawing and specific embodiment technical scheme of the present invention is done further introduction.
Embodiment 1
A kind of eukaryotic gene target practice method of not having species restriction lifeless matter safety issue of present embodiment the steps include:
(1) design of CRISPR/Cas9 and chimeric RNA and structure
1) codon of optimization coding Cas9
Cas9 belongs to the second class CRISPR/Cas system, to derive from prokaryotic cell prokaryocyte, in order can in eukaryotic cell, expressing better, at first Cas9 encoding sequence process to be optimized, do not changing under the amino acid whose prerequisite, using the codon of coded amino acid in the eukaryotic cell;
2) Cas9 nuclease vector construction and Cas9 nuclease mRNA are synthetic
According to the sequence after the step 1) optimization, the dna sequence dna of customization composite coding Cas9 nuclease, and it is inserted into respectively in the following expression vector forms: except containing carrier pST1374-Cas9 all sequences, also have the sequence NLS of a Codocyte nuclear localization signal and the sequence of a code tag albumen Flag on this carrier of pST1374-Cas9, pST1374-NLS-Flag-Cas9();
Utilize Cas9C-NLS Cla For and two primers of Cas9C-NLS Apa Rev (primer sequence sees Table 1), by dna fragmentation of chain polymerization enzyme reaction (PCR) amplification, use dna fragmentation and the pST1374-NLS-Flag-Cas9 of two digestion with restriction enzyme amplifications of ClaI and ApaI, the dna fragmentation of amplification is inserted into pST1374-NLS-Flag-Cas9, make up the pST1374-NLS-Flag-Cas9-NLS carrier, except containing carrier pST1374-Cas9 all sequences, also have the sequence NLS of former and later two Codocyte nuclear localization signals and the sequence of a code tag albumen Flag on this carrier;
It is that template (template sequence sees Table 1) pcr amplification comes out with the oligonucleotide that the sequence of three nucleus signal for locating NLS of encoding is utilized Cas9-N-3NLS For and Cas9-N-3NLS Rev primer (primer sequence sees Table 1), the PCR product is behind NheI and two digestion with restriction enzyme of NotI, be inserted in the pST1374-NLS-Flag-Cas9 carrier by same restriction enzyme site again, make up pST1374-3XNLS-Flag-Cas9, except containing carrier pST1374-Cas9 all sequences, also have the sequence NLS of three Codocyte nuclear localization signals and the sequence of a code tag albumen Flag on this carrier;
Spirane structure (Helix) dna sequence dna (seeing Table 2) is inserted into after synthetic in the middle of the sequence and coding Cas9 nuclease sequence of code tag albumen Flag through customizing, form the pST1374-NLS-Flag-Helix-Cas9 carrier, on this carrier except containing carrier pST1374-Cas9 all sequences, the sequence NLS that also has a Codocyte nuclear localization signal, the sequence of a code tag albumen Flag and a spirane structure dna sequence dna;
The Cas9 system derives from prokaryotic cell prokaryocyte, is difficult to shift to nucleus in eukaryotic cell, thereby can't guarantees that this system realizes its shearing function in eukaryotic cell.The present invention has solved this problem by adding the expression of spirane structure dna sequence dna increase Cas9 in eukaryotic cells nuclear between cell nucleus signal for locating sequence and Cas9 encoding sequence, sees Fig. 2.In this process, used human 293T.
Present embodiment has also made up the expression vector of a series of Cas9 of containing, and these carrier transfections afterwards just can be showed that by the immunostaining reaction Cas9 is in intracellular location situation in cell.Before the cell transfecting, with cell culture on the cover plate of poly-lysine bag quilt, utilize the Lipofectamine2000 transfection reagent that Cas9 series plasmid DNA transfection is gone in the 293T cell.In immunostaining experiment, at room temperature with cell fixation 15 minutes, PBS washed twice to the Paraformaldehyde 96 with 4% with damping fluid, added 0.2% Triton X-100 immersion 5 minutes with PBS again, washed twice with PBS again.With sealing under the normal lowlenthal serum room temperature 1 hour, will resist the antibody of label protein FLAG to add in the confining liquid incubated at room 2 hours more afterwards.After the PBS cleaning, again with two anti-and Hoechst incubated at room cells of the goat anti-mouse that is dissolved in the cy3 combination among the PBS 1 hour, after the PBS cleaning, cell is cultivated fluid-tight with Vectashield close, take the fluorescence photo (see figure 2) with Olympus Flueview1000 Laser Scanning Confocal Microscope then.Only Cas9 is expressed adding the spirane structure dna sequence dna between cell nucleus signal for locating sequence and Cas9 encoding sequence in eukaryotic cells nuclear, ensure that further it exercises the shearing function in gene targeting.
Cas9 nuclease serial carrier obtains Cas9 nuclease mRNA after utilizing T7Ultra Kit in-vitro transcription after the AgeI linearizing, can be directly used in gene targeting; Because the unstable of mRNA, can the long-term existence organism in, can not produce further influence to environment, thereby not have the biological safety problem.
3) chimeric RNA's is synthetic
The section of having T7 promoter sequence on the chimeric RNA template, this is to be (template sequence sees Table 1) that template produces by PCR with synthetic oligonucleotide, utilize T7Shortscript Kit in-vitro transcription to go out chimeric RNA, it comprises crRNA and tracrRNA structure, can be directed in conjunction with the site on the target DNA;
(2) translation back formation Cas9 nuclease is combined with chimeric RNA in the Cas9mRNA body, realize the fixed point shearing, shear the back and produce the dna double splitting of chain, introduce foreign DNA by the natural DNA repair process of inducing cell self " non-homogeneous terminal the connection ", thereby revise the cell native gene; See Fig. 1.
Table 1
Figure BDA00002777375000051
Figure BDA00002777375000061
Italic, binding sequence; Black matrix, the T7 promotor.
Table 2
Figure BDA00002777375000062

Claims (2)

1. an eukaryotic gene target practice method of not having species restriction lifeless matter safety issue the steps include:
(1) design of CRISPR/Cas9 and chimeric RNA and structure
1) codon of optimization coding Cas9
2) Cas9 nuclease vector construction and Cas9 nuclease mRNA are synthetic
Sequence after optimizing according to step 1), the dna sequence dna of customization composite coding Cas9 nuclease, and it is inserted into respectively in the following expression vector forms: pST1374-Cas9, pST1374-NLS-Flag-Cas9;
Utilize Cas9 C-NLS Cla For and two primers of Cas9 C-NLS Apa Rev, by dna fragmentation of chain polymerization enzyme reaction amplification, use dna fragmentation and the pST1374-NLS-Flag-Cas9 of two digestion with restriction enzyme amplifications of ClaI and ApaI, the dna fragmentation of amplification is inserted into pST1374-NLS-Flag-Cas9, makes up the pST1374-NLS-Flag-Cas9-NLS carrier;
The sequence of three nucleus signal for locating NLS of encoding utilizes Cas9-N-3NLS For and Cas9-N-3NLS Rev primer to come out for the template pcr amplification with the oligonucleotide, the PCR product is behind NheI and two digestion with restriction enzyme of NotI, be inserted in the pST1374-NLS-Flag-Cas9 carrier by same restriction enzyme site again, make up pST1374-3XNLS-Flag-Cas9;
The spirane structure dna sequence dna is inserted into after synthetic in the middle of the sequence and coding Cas9 nuclease sequence of code tag albumen Flag through customizing, and forms the pST1374-NLS-Flag-Helix-Cas9 carrier;
Cas9 nuclease serial carrier obtains Cas9 nuclease mRNA after utilizing T7 Ultra Kit in-vitro transcription after the AgeI linearizing, be directly used in gene targeting;
3) chimeric RNA's is synthetic
T7 promoter sequence on the chimeric RNA template is to be that template is passed through the chain polymerization enzyme reaction and produced with synthetic oligonucleotide, utilizes T7 Shortscript Kit in-vitro transcription to go out chimeric RNA;
(2) translation back formation Cas9 nuclease is combined with chimeric RNA in the Cas9mRNA body, realize the fixed point shearing, shear the back and produce the dna double splitting of chain, introduce foreign DNA by the natural DNA repair process of inducing cell self " non-homogeneous terminal the connection ", thereby revise the cell native gene.
2. a spirane structure dna sequence dna is characterized in that, the ability that the consideration convey of this spirane structure dna sequence dna enhancing albumen under nuclear localization signal instructs moves ability and is combined with nucleic acid, and its gene order is:
ctggaacccggcgagaagccatacaaatgcccagagtgtggtaaatctttctctcagtctggtgctctgaccagacaccagcggacccacactaga。
CN201310028668.2A 2013-01-25 2013-01-25 Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence Expired - Fee Related CN103233028B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310028668.2A CN103233028B (en) 2013-01-25 2013-01-25 Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310028668.2A CN103233028B (en) 2013-01-25 2013-01-25 Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence

Publications (2)

Publication Number Publication Date
CN103233028A true CN103233028A (en) 2013-08-07
CN103233028B CN103233028B (en) 2015-05-13

Family

ID=48881094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310028668.2A Expired - Fee Related CN103233028B (en) 2013-01-25 2013-01-25 Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence

Country Status (1)

Country Link
CN (1) CN103233028B (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103397018A (en) * 2013-08-20 2013-11-20 中国医学科学院医学生物学研究所 Site-directed modification method for DNA viral genome
CN103667338A (en) * 2013-11-28 2014-03-26 中国科学院遗传与发育生物学研究所 Fixed-point modification method for corn genome
CN104109687A (en) * 2014-07-14 2014-10-22 四川大学 Construction and application of Zymomonas mobilis CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-association proteins)9 system
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CN106232823A (en) * 2014-02-18 2016-12-14 杜克大学 The compositions of inactivation of viruses duplication and preparation and application thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN107109495A (en) * 2014-11-11 2017-08-29 伊鲁米那股份有限公司 Use the polynucleotide amplification of CRISPR cas systems
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10093910B2 (en) 2015-08-28 2018-10-09 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN109310784A (en) * 2015-12-07 2019-02-05 阿克生物公司 Methods and compositions for making and using guide nucleic acids
US10266851B2 (en) 2016-06-02 2019-04-23 Sigma-Aldrich Co. Llc Using programmable DNA binding proteins to enhance targeted genome modification
CN110616189A (en) * 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 Preparation and application of universal targeting CD19 antigen chimeric receptor T cell
CN110616233A (en) * 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 Method for efficiently knocking out primary T cell gene by CRISPR-Cas9 and application thereof
US10526589B2 (en) 2013-03-15 2020-01-07 The General Hospital Corporation Multiplex guide RNAs
CN110669746A (en) * 2012-10-23 2020-01-10 基因工具股份有限公司 Compositions for cleaving target DNA and uses thereof
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIN SHEN等: "Generation of gene-modified mice via Cas9/RNA-mediated gene targeting", 《CELL RESEARCH》 *
GIEDRIUS GASIUNAS等: "Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", 《PNAS》 *
LE CONG等: "Multiplex Genome Engineering Using CRISPR/Cas Systems", 《SCIENCE》 *
PRASHANT MALI等: "RNA-Guided Human Genome Engineering via Cas9", 《SCIENCE》 *

Cited By (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10711257B2 (en) 2011-12-30 2020-07-14 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10954498B2 (en) 2011-12-30 2021-03-23 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10435678B2 (en) 2011-12-30 2019-10-08 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US11939604B2 (en) 2011-12-30 2024-03-26 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10570419B2 (en) 2012-05-25 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10597680B2 (en) 2012-05-25 2020-03-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982231B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11970711B2 (en) 2012-05-25 2024-04-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982230B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10900054B2 (en) 2012-05-25 2021-01-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US12123015B2 (en) 2012-05-25 2024-10-22 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988782B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10793878B1 (en) 2012-05-25 2020-10-06 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10774344B1 (en) 2012-05-25 2020-09-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10752920B2 (en) 2012-05-25 2020-08-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11814645B2 (en) 2012-05-25 2023-11-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11674159B2 (en) 2012-05-25 2023-06-13 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988780B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US12215343B2 (en) 2012-05-25 2025-02-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11001863B2 (en) 2012-05-25 2021-05-11 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11634730B2 (en) 2012-05-25 2023-04-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10676759B2 (en) 2012-05-25 2020-06-09 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10669560B2 (en) 2012-05-25 2020-06-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10640791B2 (en) 2012-05-25 2020-05-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11549127B2 (en) 2012-05-25 2023-01-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11479794B2 (en) 2012-05-25 2022-10-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008589B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11473108B2 (en) 2012-05-25 2022-10-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11401532B2 (en) 2012-05-25 2022-08-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11332761B2 (en) 2012-05-25 2022-05-17 The Regenis of Wie University of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10113167B2 (en) 2012-05-25 2018-10-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008590B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10626419B2 (en) 2012-05-25 2020-04-21 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10612045B2 (en) 2012-05-25 2020-04-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10415061B2 (en) 2012-05-25 2019-09-17 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11293034B2 (en) 2012-05-25 2022-04-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11274318B2 (en) 2012-05-25 2022-03-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10227611B2 (en) 2012-05-25 2019-03-12 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11028412B2 (en) 2012-05-25 2021-06-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11242543B2 (en) 2012-05-25 2022-02-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10266850B2 (en) 2012-05-25 2019-04-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10301651B2 (en) 2012-05-25 2019-05-28 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10308961B2 (en) 2012-05-25 2019-06-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US12180504B2 (en) 2012-05-25 2024-12-31 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10337029B2 (en) 2012-05-25 2019-07-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10351878B2 (en) 2012-05-25 2019-07-16 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358658B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358659B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10577631B2 (en) 2012-05-25 2020-03-03 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10385360B2 (en) 2012-05-25 2019-08-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10400253B2 (en) 2012-05-25 2019-09-03 The Regents Of The University Of California Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription
US12180503B2 (en) 2012-05-25 2024-12-31 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10563227B2 (en) 2012-05-25 2020-02-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10407697B2 (en) 2012-05-25 2019-09-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10421980B2 (en) 2012-05-25 2019-09-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10428352B2 (en) 2012-05-25 2019-10-01 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10550407B2 (en) 2012-05-25 2020-02-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10443076B2 (en) 2012-05-25 2019-10-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11186849B2 (en) 2012-05-25 2021-11-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10487341B2 (en) 2012-05-25 2019-11-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10533190B2 (en) 2012-05-25 2020-01-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10513712B2 (en) 2012-05-25 2019-12-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10526619B2 (en) 2012-05-25 2020-01-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10519467B2 (en) 2012-05-25 2019-12-31 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
CN110669746B (en) * 2012-10-23 2024-04-16 基因工具股份有限公司 Composition for cutting target DNA and use thereof
CN110669746A (en) * 2012-10-23 2020-01-10 基因工具股份有限公司 Compositions for cleaving target DNA and uses thereof
US10745716B2 (en) 2012-12-06 2020-08-18 Sigma-Aldrich Co. Llc CRISPR-based genome modification and regulation
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US11312953B2 (en) 2013-03-14 2022-04-26 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9410198B2 (en) 2013-03-14 2016-08-09 Caribou Biosciences, Inc. Compostions and methods of nucleic acid-targeting nucleic acids
US9725714B2 (en) 2013-03-14 2017-08-08 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9803194B2 (en) 2013-03-14 2017-10-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9809814B1 (en) 2013-03-14 2017-11-07 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9909122B2 (en) 2013-03-14 2018-03-06 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10125361B2 (en) 2013-03-14 2018-11-13 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US10544433B2 (en) 2013-03-15 2020-01-28 The General Hospital Corporation Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
US12065668B2 (en) 2013-03-15 2024-08-20 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10119133B2 (en) 2013-03-15 2018-11-06 The General Hospital Corporation Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
US11168338B2 (en) 2013-03-15 2021-11-09 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US11098326B2 (en) 2013-03-15 2021-08-24 The General Hospital Corporation Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
US10378027B2 (en) 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10844403B2 (en) 2013-03-15 2020-11-24 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US10415059B2 (en) 2013-03-15 2019-09-17 The General Hospital Corporation Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
US11634731B2 (en) 2013-03-15 2023-04-25 The General Hospital Corporation Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
US11920152B2 (en) 2013-03-15 2024-03-05 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US10138476B2 (en) 2013-03-15 2018-11-27 The General Hospital Corporation Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10526589B2 (en) 2013-03-15 2020-01-07 The General Hospital Corporation Multiplex guide RNAs
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
CN103397018B (en) * 2013-08-20 2015-04-22 中国医学科学院医学生物学研究所 Site-directed modification method for DNA viral genome
CN103397018A (en) * 2013-08-20 2013-11-20 中国医学科学院医学生物学研究所 Site-directed modification method for DNA viral genome
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
CN103667338B (en) * 2013-11-28 2016-01-27 中国科学院遗传与发育生物学研究所 A kind of Fixed-point modification method for corn genome
CN103667338A (en) * 2013-11-28 2014-03-26 中国科学院遗传与发育生物学研究所 Fixed-point modification method for corn genome
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US12215365B2 (en) 2013-12-12 2025-02-04 President And Fellows Of Harvard College Cas variants for gene editing
CN106232823A (en) * 2014-02-18 2016-12-14 杜克大学 The compositions of inactivation of viruses duplication and preparation and application thereof
CN104109687A (en) * 2014-07-14 2014-10-22 四川大学 Construction and application of Zymomonas mobilis CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-association proteins)9 system
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN107109495A (en) * 2014-11-11 2017-08-29 伊鲁米那股份有限公司 Use the polynucleotide amplification of CRISPR cas systems
US12065695B2 (en) 2014-11-11 2024-08-20 Illumina, Inc. Polynucleotide amplification using CRISPR-Cas systems
CN107109495B (en) * 2014-11-11 2021-12-24 伊鲁米那股份有限公司 Polynucleotide amplification using CRISPR-CAS system
US10093910B2 (en) 2015-08-28 2018-10-09 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10633642B2 (en) 2015-08-28 2020-04-28 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10526591B2 (en) 2015-08-28 2020-01-07 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US11060078B2 (en) 2015-08-28 2021-07-13 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12344869B2 (en) 2015-10-23 2025-07-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
CN109310784B (en) * 2015-12-07 2022-08-19 阿克生物公司 Methods and compositions for making and using guide nucleic acids
CN109310784A (en) * 2015-12-07 2019-02-05 阿克生物公司 Methods and compositions for making and using guide nucleic acids
US12275952B2 (en) 2016-06-02 2025-04-15 Sigma-Aldrich Co. Llc Using programmable DNA binding proteins to enhance targeted genome modification
US12084675B2 (en) 2016-06-02 2024-09-10 Sigma-Aldrich Co. Llc Using programmable DNA binding proteins to enhance targeted genome modification
US10266851B2 (en) 2016-06-02 2019-04-23 Sigma-Aldrich Co. Llc Using programmable DNA binding proteins to enhance targeted genome modification
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US12359218B2 (en) 2017-07-28 2025-07-15 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CN110616233B (en) * 2018-06-20 2022-02-22 西安桑尼赛尔生物医药有限公司 Method for efficiently knocking out primary T cell gene by CRISPR-Cas9 and application thereof
CN110616189A (en) * 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 Preparation and application of universal targeting CD19 antigen chimeric receptor T cell
CN110616233A (en) * 2018-06-20 2019-12-27 西安桑尼赛尔生物医药有限公司 Method for efficiently knocking out primary T cell gene by CRISPR-Cas9 and application thereof
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12281303B2 (en) 2019-03-19 2025-04-22 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Also Published As

Publication number Publication date
CN103233028B (en) 2015-05-13

Similar Documents

Publication Publication Date Title
CN103233028A (en) Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence
Wang et al. CRISPR technology: A decade of genome editing is only the beginning
Crozet et al. Birth of a photosynthetic chassis: a MoClo toolkit enabling synthetic biology in the microalga Chlamydomonas reinhardtii
JP7502537B2 (en) Enzymes with RUVC domains
Moon et al. Improving CRISPR genome editing by engineering guide RNAs
DeWitt et al. Genome editing via delivery of Cas9 ribonucleoprotein
Slattery et al. An expanded plasmid-based genetic toolbox enables Cas9 genome editing and stable maintenance of synthetic pathways in Phaeodactylum tricornutum
AU2023203391A1 (en) Using programmable dna binding proteins to enhance targeted genome modification
CN107250148B (en) chemically modified guide RNA
JP2023002712A (en) S. pyogenes CAS9 mutant gene and polypeptide encoded thereby
AU2016274452C1 (en) Thermostable Cas9 nucleases
Gutiérrez et al. Gene delivery technologies with applications in microalgal genetic engineering
Ghribi et al. Genome editing by CRISPR-Cas: a game change in the genetic manipulation of Chlamydomonas
US20140056868A1 (en) Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
Martinez-Garcia et al. Pseudomonas putida in the quest of programmable chemistry
CN106795521A (en) The method and composition of target gene seat for modifying
JP2015503535A5 (en)
CN109136248A (en) Multi-target editing vector and its construction method and application
Feng et al. Saccharomyces cerevisiae promoter engineering before and during the synthetic biology era
Kassaw et al. Episome-based gene expression modulation platform in the model diatom Phaeodactylum tricornutum
Rau et al. Method development progress in genetic engineering of thraustochytrids
Zhang et al. One-day TALEN assembly protocol and a dual-tagging system for genome editing
Li et al. The working dead: repurposing inactive CRISPR-associated nucleases as programmable transcriptional regulators in plants
Sato et al. Overcoming the limitations of CRISPR-Cas9 systems in Saccharomyces cerevisiae: off-target effects, epigenome, and mitochondrial editing
Rozov et al. Optimization of genome knock-in method: Search for the most efficient genome regions for transgene expression in plants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150513